Volume 6, Issue 2: The Current State of CFTR Modification- PODCAST
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 6, Issue 2)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Explain the long-term benefits of ivacaftor therapy in people with G551D CFTR mutations.
- Describe the effects of ivacaftor therapy in people with non-G551D CFTR mutations.
- Evaluate the impact of lumacaftor plus ivacaftor in people with two F508del CFTR mutations.
- Describe the current research into therapeutic options for people with CFTR class I also known as nonsense or mis-sense mutations.
Dr. Noah Lechtzin has reported that he has served as principal investigator for Vertex Pharmaceuticals Incorporated. In addition, he has served as a consultant for Hill Rom.
- 0.50 ANCC
- 0.50 Attendance